Reactions 1704, p281 - 2 Jun 2018 Pneumonitis: 3 case reports A study described three patients [ages and sexes not stated] who developed pneumonitis during treatment with nivolumab for non-small cell lung cancer. The patients started receiving nivolumab therapy at a dose of 3 mg/kg [route not stated] and developed moderate to severe grade pneumonitis [time to reactions onset not stated]. The first patient was treated with mycophenolate, prednisolone and methyprednisolone. The second patient received prednisolone and methylprednisolone, and the third patient received prednisolone only. Nivolumab was discontinued for the first two patients [outcomes not stated]. Author comment: "Immune-related adverse event such as pneumonitis can be a major concern in patients with lung cancer who may already have pre-morbid lung disease. This study describes the rates and effects of immune-related complications with nivolumab". Samaranayake C, et al. Pneumonitis and other immune related complications from nivolumab therapy in patient with non-small cell lung cancer: A descriptive study. Respirology 23 (Suppl. 1): 199 abstr. 175, Mar 2018. Available from: URL: http:// doi.org/10.1111/resp.13268 [abstract] - Australia 803323675 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera